From: Nanotechnology in cancer diagnosis: progress, challenges and opportunities
Marker | Type of cell | Type of cancer | Detection method | Reference |
---|---|---|---|---|
EpCAM | CTC | Colorectal Breast Head and neck | CellSearch | [72] |
EpCAM and FRα | CTC | Non-small cell lung cancer | CellSearch | [73] |
Glycan | CTC | Breast | Flow cytometry | [74] |
Vimentin | CTC | Gastrointestinal | Confocal microscopy | [75] |
EMT CTC | Prostate | CellSearch | [76] | |
CTC | Sarcoma | Flow cytometry | [77] | |
Vimentin+PD-L1 | CTC | Colorectal, prostate cancer | Confocal microscopy | [78] |
Synaptophysin | CTC | Castration resistant prostate cancer | CellSearch | [79] |
Major vault protein | Mesenchymal and intermediate CTCs | Hepatocellular carcinomas | Flow cytometry | [80] |
Androgen receptor | CTC | Metastatic breast cancer | Epic Sciences CTC platform | [81] |
p75 Neurotrophin receptor+EpCAM | CTC | Esophageal squamous cell carcinoma | Flow cytometry | [82] |
Carbonic anhydrase 9 and CD147 | CTC | Clear cell renal cell carcinoma | NanoVelcro | [83] |
Excision repair cross-complementation group 1 | CTC | Platinum resistance ovarian cancer | Reverse-transcription PCR | [84] |